Loading company…
Violet Therapeutics develops drug discovery programs for central nervous system and neurodegenerative diseases.
Founded in 2021 in Massachusetts, Violet Therapeutics studies cell-to-cell signaling to identify therapeutic targets for central nervous system diseases. Its CONNECT and C-to-C Engine platforms investigate neuroinflammation, neurodegeneration, and synaptic dysfunction; its lead program targets EphB3. The company works with pharmaceutical and biotechnology organizations. In May 2026, it raised USD 4.75 million in seed funding led by LifeSpan Vision Ventures, with SV Health Investors, University of Tokyo Edge Capital Partners, Ono Venture Investment, and Mass General Brigham Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in